Cargando…
Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering: current evidence, clinical implications, and future perspectives
The clinical efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in reducing major cardiovascular adverse events related to atherosclerotic cardiovascular disease (ASCVD) has been well established in recent large randomized outcome trials. Although the cardiovascular and al...
Autores principales: | Zhou, Xin, Li, Ziping, Liu, Hangkuan, Li, Yongle, Zhao, Dong, Yang, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129148/ https://www.ncbi.nlm.nih.gov/pubmed/36806078 http://dx.doi.org/10.1097/CM9.0000000000002057 |
Ejemplares similares
-
Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention
por: Liu, Hangkuan, et al.
Publicado: (2021) -
Next-generation antithrombotics in ischemic stroke: preclinical perspective on ‘bleeding-free antithrombosis'
por: Kraft, Peter, et al.
Publicado: (2012) -
Fatal Renal Bleeding in a Patient Treated With Aggressive Antithrombotic Therapy After Recurrent Coronary Stent Thrombosis
por: Moon, Jeonggeun, et al.
Publicado: (2010) -
Major gastrointestinal bleeding and antithrombotics: Characteristics and management
por: Bouget, Jacques, et al.
Publicado: (2020) -
Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome
por: Towashiraporn, Korakoth, et al.
Publicado: (2022)